Key facts
- It has raised $480K; the latest was Early Stage VC ($440K) in Feb 2026.
- Notable investors include SFC Capital, Zinc, Barclays Eagle Lab, The Francis Crick Institute.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Cambridge Medixine
- ·The full record, as it builds
Funding rounds
No funding rounds for Cambridge Medixine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cambridge Medixine
Operator of a next-generation therapeutics firm intended to deliver safer, easier, and faster medicines using advanced mRNA technology. The company offers drug delivery systems, personalized treatment options, and robust safety measures, enabling healthcare providers to improve drug delivery, reduce side effects, and expand the accessibility and effectiveness of RNA medicines for a range of conditions.
- Sector
- Healthcare
- HQ
- Ely, United Kingdom
- Founded
- 2023
- Employees
- 5
- Website
- cammed.co.uk/
- Ownership
- Privately Held (backing)
Cambridge Medixine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cambridge Medixine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cambridge Medixine in its N-PORT filings yet. We sweep new filings monthly.